Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept for Polypoidal Choroidal Vasculopathy (EPIC)
NCT01871376Phase 4Completed
- Start
- May 2013
- Primary completion
- Sep 2016
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label trial of aflibercept in polypoidal choroidal vasculopathy (PCV) (2 arms). Primary endpoint: Efficacy of intravitreal aflibercept injection at 2 Years. Started May 2013; status: completed.
02
Drugs
aflibercept
03
Conditions
polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on NCT01871376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01871376.